Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.

Autor:	Motamed M; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences., Karimi H; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences., Sanjari Moghaddam H; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences., Taherzadeh Boroujeni S; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences., Sanatian Z; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences., Hasanzadeh A; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences., Khodaei Ardakani MR; Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran., Akhondzadeh S; Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences.
Jazyk:	angličtina
Zdroj:	International clinical psychopharmacology [Int Clin Psychopharmacol] 2022 May 01; Vol. 37 (3), pp. 92-101.
DOI:	10.1097/YIC.0000000000000399
Abstrakt:	This study aimed to investigate the efficacy and safety of antitumor necrosis factor-alpha (TNF-α) therapy using adalimumab in patients with chronic schizophrenia. This is a randomized, double-blind, placebo-controlled clinical trial carried out at Roozbeh Hospital (Tehran, Iran) from June 2020 to October 2021. The patients were randomly divided into two parallel adalimumab + risperidone and placebo + risperidone groups. Participants in the intervention group received adalimumab subcutaneous injection (40 mg) by pen-injector at weeks 0 and 4. Using the Positive and Negative Symptoms Scale (PANSS), patients' positive and negative symptoms were assessed at weeks 0, 4, and 8. Forty patients (20 in each group) were included. PANSS total (t = 4.43, df = 38, P < 0.001), negative (t = 2.88, df = 38, P = 0.006), and general psychopathology (t = 4.06, df = 38, P < 0.001) scores demonstrated a significantly greater decline in adalimumab compared with the placebo group from baseline study endpoint. However, improvement of PANSS positive subscale scores showed no significant difference from the baseline study endpoint. There was no significant between-group difference regarding levels of C-reactive protein, interleukin (IL)-1β, TNF-α, IL-6, and IL-8 at baseline and also at the week 8 visit (P > 0.05 for all). The current study found adalimumab adjunctive therapy effective in treating schizophrenia, particularly its negative and general psychopathology symptoms, with no side effects. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu